Recruitment unclearEUCTR 2006-005512-27
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesADHD
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · France and 6 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 400
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-005512-27
- Official title
Show the full official title
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac...
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · France · Ireland
5 more locations
- Italy
- Netherlands
- Norway
- Spain
- United Kingdom
Registry details
Historical country statuses
- Belgium — Completed
- Spain — Completed
- France — Completed
- United Kingdom — Completed
- Ireland — Completed
- Italy — Completed
- Netherlands — Not Authorised
- Norway — Ongoing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Want to explore more studies?
Explore studiesRelated studies
A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in a...
A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate